Spero Therapeutics Q2 net loss $17.9M; CMO departs; SPR720 data expected 4Q 2024

Spero Therapeutics, Inc.

2024-Q2 EPS reported -$0.57 revenue$19,464,000

Net loss $17.9M ($0.33/share) vs $11.9M loss ($0.23) in Q2 2023; revenue $10.2M up from $2.7M.
Cash $63.5M as of June 30, 2024; runway into late 2025 reaffirmed.
SPR720 Phase 2a NTM-PD trial enrollment completed; preliminary data expected 4Q 2024.
CMO Kamal Hamed departing Aug 29; Board member John Pottage appointed Special Advisor to oversee medical function.
Tebipenem HBr Phase 3 PIVOT-PO enrollment on track; target ~2,648 patients, completion H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.